Acuitas Investments LLC Takes Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Acuitas Investments LLC acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 49,016 shares of the company’s stock, valued at approximately $962,000. Acuitas Investments LLC owned approximately 0.16% of Fulgent Genetics as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in FLGT. nVerses Capital LLC purchased a new stake in shares of Fulgent Genetics in the 2nd quarter valued at $43,000. Signaturefd LLC boosted its position in Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after buying an additional 1,132 shares during the period. State Board of Administration of Florida Retirement System purchased a new stake in Fulgent Genetics during the 1st quarter valued at $178,000. Acadian Asset Management LLC purchased a new stake in Fulgent Genetics during the 1st quarter valued at $195,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Fulgent Genetics during the 1st quarter valued at $213,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Insider Transactions at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the sale, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 4,324 shares of company stock valued at $98,717. Company insiders own 31.76% of the company’s stock.

Fulgent Genetics Stock Up 2.0 %

Shares of FLGT opened at $21.90 on Friday. The stock has a market capitalization of $655.34 million, a P/E ratio of -3.93 and a beta of 1.37. The firm has a fifty day simple moving average of $22.45 and a two-hundred day simple moving average of $21.87. Fulgent Genetics, Inc. has a twelve month low of $18.91 and a twelve month high of $31.95.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings results on Friday, August 2nd. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. During the same quarter in the prior year, the company posted ($0.33) EPS. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Sell-side analysts expect that Fulgent Genetics, Inc. will post -1.46 EPS for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.